TG Therapeutics (TGTX) News & Sentiment

TGTX's Briumvi has performed well by regularly exceeding earnings expectations, even though it faced competition from Roche's Zunovo. Its advantages include a quicker infusion time, reduced risks of cancer, and a better price compared to Ocrevus. TGTX is financially stable, with a market cap of $5.7 billion and a strong cash reserve that guarantees long-term funding.

After TG Therapeutics reported better-than-expected results for the fourth quarter, its stock became very popular among investors recently. Data from S&P Global Market Intelligence shows that by Friday afternoon, the biotech company's share price had increased by nearly 27% this week.

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) has announced its schedule for presentations on BRIUMVI® (ublituximab-xiiy) data related to patients with relapsing forms of multiple sclerosis (RMS) at the American Academy of Neurology's annual meeting, taking place from April 5 to 9, 2025, in San Diego, California. The abstracts are now available online and can be found on the AAN meeting website at https://www.aan.com/events/annual-meeting-abstracts. More details about the upcoming presentations are provided below.

TG Therapeutics, Inc. (NASDAQ:TGTX) will hold its Q4 2024 Earnings Conference Call on March 3, 2025, at 8:30 AM ET. The call will feature company representatives including Jenna Bosco, Michael Weiss, Adam Waldman, and Sean Power. Participants from various financial institutions will also join the call, including Prakhar Agrawal from Cantor Fitzgerald and Michael DiFiore from Evercore ISI.

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) has announced a conference call scheduled for Monday, March 3, 2025, at 8:30 AM ET. The call will cover the results for the fourth quarter and the entire year of 2024, as well as the company's plans for 2025. Michael S.

TG Therapeutics shared updates at the JP Morgan Healthcare conference this month, with CEO Weiss discussing both commercial progress and pipeline developments. Briumvi showed impressive sales of $103.6 million in Q4 2024, indicating its growth potential even with new competition from Roche's Ocrevus Zunovo. Additionally, the company announced that subcutaneous Briumvi will begin phase 3 trials in mid-2025, and they are also working on new trials to enhance the convenience of IV Briumvi and expand its use in myasthenia gravis.

TG Therapeutics surpassed its 2024 revenue expectations by 24%, showing impressive growth and gaining market share with its Multiple Sclerosis drug, Briumvi. Although the revenue forecast for 2025 is $540 million, which suggests slower growth, management believes there is a chance for much higher earnings, potentially hitting $605 million. The CEO's remarks and the performance in the fourth quarter point to a steady increase of 15-20% in new patients, supported by future advertising and greater recognition among influential experts.

TG Therapeutics (TGTX) saw significant movement in the last trading session with trading volume above average. However, the recent changes in earnings estimates may not support the stock's upward momentum in the short term.

TG Therapeutics is currently selling an IV infusion of Briumvi and is also working on a subcutaneous version to better compete with other multiple sclerosis treatments. The company plans to share initial results for the subcutaneous Briumvi in early 2025, and they are optimistic about its potential. Although they have authorized a $100 million share buyback, they only repurchased $2.1 million in the third quarter of 2024, but more buybacks could help support the stock price.